CN107108634B - 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物 - Google Patents

作为PI3Kβ抑制剂的咪唑并哒嗪衍生物 Download PDF

Info

Publication number
CN107108634B
CN107108634B CN201580069133.7A CN201580069133A CN107108634B CN 107108634 B CN107108634 B CN 107108634B CN 201580069133 A CN201580069133 A CN 201580069133A CN 107108634 B CN107108634 B CN 107108634B
Authority
CN
China
Prior art keywords
alkyl
group
substituents
mmol
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580069133.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107108634A (zh
Inventor
L.A.梅维勒
L.米波伊
S.考帕
V.S.邦塞勒特
I.N.C.皮拉特
E.T.J.帕斯奎尔
D.J-C.伯特洛特
O.A.G.奎伊罗勒
C.梅耶
P.R.安吉鲍德
C.G.M.德梅斯特雷
G.J.M.梅塞伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN107108634A publication Critical patent/CN107108634A/zh
Application granted granted Critical
Publication of CN107108634B publication Critical patent/CN107108634B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Taps Or Cocks (AREA)
CN201580069133.7A 2014-12-19 2015-12-18 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物 Expired - Fee Related CN107108634B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199322 2014-12-19
EPEP14199322.0 2014-12-19
PCT/EP2015/080604 WO2016097347A1 (en) 2014-12-19 2015-12-18 IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS

Publications (2)

Publication Number Publication Date
CN107108634A CN107108634A (zh) 2017-08-29
CN107108634B true CN107108634B (zh) 2020-09-15

Family

ID=52134002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580069133.7A Expired - Fee Related CN107108634B (zh) 2014-12-19 2015-12-18 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物

Country Status (26)

Country Link
US (1) US10087187B2 (enExample)
EP (1) EP3233862B1 (enExample)
JP (1) JP6568588B2 (enExample)
KR (1) KR20170095239A (enExample)
CN (1) CN107108634B (enExample)
AU (1) AU2015366190B2 (enExample)
BR (1) BR112017012930A2 (enExample)
CA (1) CA2967551A1 (enExample)
CY (1) CY1122381T1 (enExample)
DK (1) DK3233862T3 (enExample)
EA (1) EA029789B1 (enExample)
ES (1) ES2761051T3 (enExample)
HR (1) HRP20191550T1 (enExample)
HU (1) HUE045220T2 (enExample)
IL (1) IL252866B (enExample)
LT (1) LT3233862T (enExample)
MA (1) MA41174B1 (enExample)
MD (1) MD3233862T2 (enExample)
ME (1) ME03517B (enExample)
MX (1) MX2017008074A (enExample)
PL (1) PL3233862T3 (enExample)
PT (1) PT3233862T (enExample)
RS (1) RS59301B1 (enExample)
SI (1) SI3233862T1 (enExample)
SM (1) SMT201900509T1 (enExample)
WO (1) WO2016097347A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382601B (es) 2015-10-09 2025-03-13 Janssen Pharmaceutica Nv DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
HRP20210508T1 (hr) 2016-06-16 2021-05-28 Janssen Pharmaceutica Nv Biciklički derivati piridina, pirazina i pirimidina kao inhibitori pi3k beta
EA201992296A1 (ru) 2017-03-29 2020-02-12 Янссен Фармацевтика Нв Производные хиноксалина и пиридопиразина в качестве ингибиторов pi3k-бета
IL285315B2 (en) 2019-02-07 2025-12-01 Beigene Ltd Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
CN110128505A (zh) * 2019-05-21 2019-08-16 梯尔希（南京）药物研发有限公司 一种戈舍瑞林杂质的合成方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009060197A1 (en) * 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
WO2009106577A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2011047770A2 (de) * 2009-10-19 2011-04-28 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
WO2014078211A1 (en) * 2012-11-14 2014-05-22 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US20090215818A1 (en) 2006-07-24 2009-08-27 Smithkline Beecham Corporation Thiozolidinedione derivatives as pi3 kinase inhibitors
CA2663091A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
WO2011058109A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP3170813B1 (en) * 2010-10-06 2018-12-12 GlaxoSmithKline LLC Benzimidazole derivatives as pi3 kinase inhibitors
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
GB201321734D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008138834A1 (en) * 2007-05-09 2008-11-20 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2009060197A1 (en) * 2007-11-08 2009-05-14 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazopyridazines for use as protein kinase inhibitors
WO2009106577A1 (en) * 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
WO2010007099A1 (en) * 2008-07-15 2010-01-21 Cellzome Limited 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors
WO2011047770A2 (de) * 2009-10-19 2011-04-28 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
WO2013095761A1 (en) * 2011-12-20 2013-06-27 Glaxosmithkline Llc Imidazopyridine derivatives as pi3 kinase inhibitors
WO2014078211A1 (en) * 2012-11-14 2014-05-22 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators and methods of use

Also Published As

Publication number Publication date
HUE045220T2 (hu) 2019-12-30
JP6568588B2 (ja) 2019-08-28
DK3233862T3 (da) 2019-10-07
WO2016097347A1 (en) 2016-06-23
AU2015366190A1 (en) 2017-05-25
PT3233862T (pt) 2019-10-09
ES2761051T3 (es) 2020-05-18
US20180002336A1 (en) 2018-01-04
EA201791396A1 (ru) 2017-10-31
PL3233862T3 (pl) 2020-01-31
AU2015366190B2 (en) 2020-01-23
KR20170095239A (ko) 2017-08-22
EA029789B1 (ru) 2018-05-31
SI3233862T1 (sl) 2019-09-30
SMT201900509T1 (it) 2019-11-13
LT3233862T (lt) 2019-09-10
JP2017538734A (ja) 2017-12-28
MA41174B1 (fr) 2019-09-30
MX2017008074A (es) 2018-01-09
IL252866B (en) 2020-09-30
US10087187B2 (en) 2018-10-02
MD3233862T2 (ro) 2019-11-30
HRP20191550T1 (hr) 2019-11-29
RS59301B1 (sr) 2019-10-31
ME03517B (me) 2020-04-20
BR112017012930A2 (pt) 2018-01-09
CA2967551A1 (en) 2016-06-23
IL252866A0 (en) 2017-08-31
CY1122381T1 (el) 2021-01-27
EP3233862B1 (en) 2019-07-03
MA41174A (fr) 2017-10-25
EP3233862A1 (en) 2017-10-25
CN107108634A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
CN109311843B (zh) 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物
CN104011052B (zh) 化合物
CN115702025A (zh) 稠合三环kras抑制剂
CN104507931B (zh) 新化合物
JP2024519170A (ja) 化合物
CN106164075B (zh) 大环嘧啶衍生物
CN106132964B (zh) 大环吡啶衍生物
CN107108634B (zh) 作为PI3Kβ抑制剂的咪唑并哒嗪衍生物
CN107108633B (zh) 作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
EP3601254B1 (en) Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors
HK40003076A (zh) 作为PI3Kβ抑制剂的二环吡啶、二环吡嗪、和二环嘧啶衍生物
HK40003079A (en) Azabenzimidazole derivatives as pi3k beta inhibitors
BR112018075999B1 (pt) Derivados de piridina, pirazina e pirimidina bicíclicos como inibidores de pi3k beta

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200915